Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Article Title: Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.
doi: 10.1158/1078-0432.CCR-19-1822
Figure Lengend Snippet: Pharmacodynamic analysis of eribulin, irinotecan and the combination in ES-4 xenografts. (A) Immunoblotting of three independent ES-4 tumor lysates for markers of mitotic arrest (P-S10-histone H3), DNA damage, (P-S139-H2A.X; P-S345-Chk1; P-T68-Chk2; RRM2B, ribonucleotide reductase regulatory TP53-inducible subunit M2B), TP53-regulated genes (TP53; cyclin dependent kinase inhibitor 1A, p21; MDM2; PUMA) and apoptosis (full length and cleaved caspase 3; cleaved PARP). GAPDH was used as a loading control. (B) Immunohistochemistry for TP53 in ES-4 xenografts treated with eribulin, irinotecan or the combination. Tumors were excised and processed at 24h and 144h after the first drug dose. (C) Quantification of TP53 staining in ES-4 xenografts. *p < 0.033, **p < 0.002, ***p < 0.001 compared to control; #p < 0.033 compared to eribulin + irinotecan at 24 h; $p < 0.033, $$p < 0.002 compared to eribulin + irinotecan at 144h, two-way ANOVA with Tukey’s post-hoc test. ERB, eribulin; IRN, irinotecan; ERB+IRN, combination treatment.
Article Snippet: Proteins were transferred to Immobilon-FL PVDF membranes (MilliporeSigma) and probed with antibodies for cleaved PARP (Cell Signaling #5625), phospho-S139-H2A.X (#9718), TP53 (#48818), CDKN1A/p21 (#2947), MDM2 (#86934), PUMA/BBC3 (#12450) phospho-S345-Chk1 (#2348), Chk1 (#2360), phospho-T68-Chk2 (#2197), Chk2 (#3440), full length/cleaved caspase 3 (#9668), cleaved caspase 3 (#9664), phospho-S10-histone H3 (#53348), histone H3 (#4499), GAPDH (#2118) or RRM2B/p53R2 (Invitrogen #PA5–19970).
Techniques: Western Blot, Immunohistochemistry, Staining